Higher Stem Cell Dose Infusion after Intensive Chemotherapy Does Not Improve Symptom Burden in Older Patients with Multiple Myeloma and Amyloidosis  Nina Shah, Qiuling Shi, Loretta A. Williams, Tito R. Mendoza, Xin Shelley Wang, James M. Reuben, Patrick M. Dougherty, Qaiser Bashir, Muzaffar H. Qazilbash, Richard E. Champlin, Charles S. Cleeland, Sergio A. Giralt  Biology of Blood and Marrow Transplantation  Volume 22, Issue 2, Pages 226-231 (February 2016) DOI: 10.1016/j.bbmt.2015.07.036 Copyright © 2016 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 1 Patient enrollment and disposition. Biology of Blood and Marrow Transplantation 2016 22, 226-231DOI: (10.1016/j.bbmt.2015.07.036) Copyright © 2016 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 2 Symptom burden throughout ASCT course for (A) all patients (n = 74) and (B) the subset of patients with amyloidosis (n = 20). Curves represent mean composite severity scores of the 5 most severe symptoms reported. As we have seen in previous studies, symptoms peaked in severity at WBC nadir. However, there were no significant differences between the AUCs of severity scores over the first 7 days (P = .819 for all patients and P = .685 for amyloid patients) or over the first 28 days (P = .863 for all patients and P = .609 for amyloid patients) during recovery after ASCT. Biology of Blood and Marrow Transplantation 2016 22, 226-231DOI: (10.1016/j.bbmt.2015.07.036) Copyright © 2016 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 3 Patient function and cytokine data. (A) Distance traveled during 6-minute walk test (feet) throughout the ASCT course. There were no significant differences noted between treatment groups (P = .221). (B) Time (seconds) to go from sitting to standing position throughout the ASCT course. No significant differences were noted between stem cell dose groups except at day −2 (2 days before stem cell infusion). (C) IL-6 levels throughout the ASCT course. Although both groups experienced an increase in serum IL-6 levels during the first week after ASCT, there were no differences in these levels between treatment groups (P = .377). Biology of Blood and Marrow Transplantation 2016 22, 226-231DOI: (10.1016/j.bbmt.2015.07.036) Copyright © 2016 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 4 Survival curves from time of ASCT. No differences between treatment groups were noted in either (A) progression-free survival or (B) overall survival (P = .43 and P = .363 respectively, by log-rank test). Biology of Blood and Marrow Transplantation 2016 22, 226-231DOI: (10.1016/j.bbmt.2015.07.036) Copyright © 2016 American Society for Blood and Marrow Transplantation Terms and Conditions